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The role of fibrinogen D domain intermolecular association sites
in the polymerization of fibrin and fibrinogen Tokyo II (gamma
275 Arg-->Cys).
M W Mosesson, … , J F Hainfeld, J S Wall
J Clin Invest. 1995;96(2):1053-1058. https://doi.org/10.1172/JCI118091.
Research Article

Intermolecular end-to-middle domain pairing between a thrombin-exposed 'A' polymerization site in the central 'E' domain
of fibrin, and a constitutive complementary 'a' site in each outer 'D' domain ('D:E'), is necessary but not alone sufficient for
normal fibrin assembly, as judged from previous studies of a congenital dysfibrinogen, Tokyo II (gamma 275 arg-->cys),
which showed defective fibrin clot assembly and a normal D:E interaction (Matsuda, M., M. Baba, K. Morimoto, and C.
Nakamikawa, 1983. J. Clin. Invest. 72:1034-1041). In addition to the 'a' polymerization site, two other constitutive
intermolecular association sites on fibrinogen D domains have been defined: between gamma chain regions containing
the carboxy-terminal factor XIIIa crosslinking site ('gamma XL:gamma XL'); and between sites located at the outer ends of
each molecule ('D:D') (Mosesson, M. W., K. R. Siebenlist, J. F. Hainfeld, and J. S. Wall, manuscript submitted for
publication). We evaluated the function of these sites in Tokyo II fibrinogen, and confirmed that there was a normal fibrin
D:E interaction, as determined from a normal fibrin crosslinking rate in the presence of factor XIIIa. We also found a
normal gamma XL: gamma XL interaction, as assessed by a normal fibrinogen crosslinking rate. Judging from electron
microscopic images, factor XIIIa-crosslinked Tokyo II fibrinogen failed to form elongated double-stranded fibrils like
normal fibrinogen. Instead, it formed aggregated disordered collections of […]
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Abstract

Introduction

Intermolecular end-to-middle domain pairing between a
thrombin-exposed 'A' polymerization site in the central 'E'
domain of fibrin, and a constitutive complementary 'a' site
in each outer 'D' domain ('D:E'), is necessary but not alone
sufficient for normal fibrin assembly, as judged from previous studies of a congenital dysfibrinogen, Tokyo II ( y275
arg-+cys), which showed defective fibrin clot assembly and
a normal D:E interaction (Matsuda, M., M. Baba, K. Morimoto, and C. Nakamikawa, 1983. J. Clin. Invest 72:10341041). In addition to the 'a' polymerization site, two other
constitutive intermolecular association sites on fibrinogen D
domains have been defined: between 'Y chain regions containing the carboxy-terminal factor XIIIa crosslinking site
('yXL:'YXL'); and between sites located at the outer ends of
each molecule ('D:D') (Mosesson, M. W., K. R. Siebenlist,
J. F. Hainfeld, and J. S. Wall, manuscript submitted for
publication). We evaluated the function of these sites in
Tokyo II fibrinogen, and confirmed that there was a normal
fibrin D:E interaction, as determined from a normal fibrin
crosslinking rate in the presence of factor XIIIa. We also
found a normal 'YXL:'YXL interaction, as assessed by a normal
fibrinogen crosslinking rate. Judging from electron microscopic images, factor XIIIa-crosslinked Tokyo II fibrinogen
failed to form elongated double-stranded fibrils like normal
fibrinogen. Instead, it formed aggregated disordered collections of molecules, with occasional short fibrillar segments.
In addition, Tokyo II fibrin formed an abnormal, extensively
branched clot network containing many tapered terminating fibers. These findings indicate that the Tokyo II fibrinogen defect results in a functionally abnormal D:D self-association site, and that a normal D:D site interaction is required,
in addition to D:E, for normal fibrin or fibrinogen assembly.
(J. Clln. Invest 1995. 96:1053-1058.) Key words: fibrinogen • dysfibrinogenemia • fibrin • factor XIII • polymerization

Fibrin polymerization begins after cleavage and release of two
amino-terminal A fibrinopeptides from the central 'E' domain
of fibrinogen molecules, exposing each of the 'A' polymerization sites they mask in precursor fibrinogen molecules (1-5).
Each exposed 'A' site then combines noncovalently with a constitutive complementary 'a' site in the outer 'D' domain of a
neighboring fibrin molecule, a necessary interaction ( 'D:E') for
producing the half-staggered, end-to-middle domain pairing that
results in twisting (6-10), double-stranded fibrils (6-14) (Fig.
1). Although it is known from many previous studies (1-5,
13, 14 inter alia) that the D:E interaction is required for normal
fibrin assembly, it is not clear whether this reaction alone is
sufficient for this process to occur.
Fibrinogen Tokyo II is an hereditary heterozygotic dysfibrinogenemia associated with defective fibrin assembly (15),
and characterized by replacement of -y275 arginine by cysteine
in affected molecular D domains ( 16). The same -y chain substitution and type of abnormal fibrin polymerization have been
reported in five other families: fibrinogens Osaka II, Tochigi,
Morioka, Baltimore IV and Milano V (16, 17). Six other -y275
mutations ( arg--+his) include fibrinogens Haifa, Bergamo II, Essen, Perugia, Saga, and Osaka m, which also display abnormal
fibrin assembly (16).
Defective fibrin assembly of fibrinogen Tokyo II is featured
by a markedly prolonged thrombin clotting time that is partially
corrected by addition of calcium (15). Tokyo II fibrinogen
bound normally to insolubilized normal fibrin, indicating that
the D:E interaction was normal. D dimers derived by plasmin
digestion of crosslinked fibrin were also normal by SOS-PAGE,
but when they were compared functionally with normal, Tokyo
II D dimers showed defective binding to fibrin fragment E. This
abnormal behavior indicated that there was a unique region in
the Tokyo II D domain, distinct from the 'a' polymerization
site, that accounted for abnormal fibrin assembly. The defective
site was tentatively ascribed to a so-called 'lateral association
site' ('bb') (18), that interacts with the E domain 'B' site that
becomes exposed after cleavage of fibrinopeptide B (4, 18).
Recently, during the course of evaluating the location of
carboxy-tenninal 'Y chain crosslinks in normal fibrin, 1 we identified two constitutive self-association sites on the fibrinogen D
domain that were each structurally and functionally distinct
from the 'a' site: between 'Y chain regions containing the carboxy-tenninal factor XIIIa crosslinking site ('-yXL:'YXL'); and
between sites located at the ends of each molecule ( 'D:D') (Fig.
1 ) . The presence of a D:D self-association site in fibrinogen or
fibrin had previously been suggested in other studies (19-21 ).
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Figure 1. Diagram showing the "transverse" arrangement of carboxyterminal 'Y chain crosslinks in a fibrin fibril based upon recent analyses
of crosslinked fibrinogen polymers. 1 Consecutive fibrin molecules comprising each fibril strand are lightly or darkly hatched. The D:E interaction between the D domain 'a' site and the E domain 'A' site is represented by a dotted line. The locations of the constitutive 'YxL:'YxL and
D:D self-association sites are indicated.

Recognition of the existence of these two self-association
sites raised the possibility that the functional abnormality in
Tokyo II fibrinogen might be related to a defect in one of them,
D:D, rather than to the so-called 'bb' site interaction. In this
report, we addressed that possibility by investigating the structure of Tokyo II fibrin and factor XIIIa-crosslinked fibrinogen
polymers in the context of the relevant functional features of
each of the D domain self-association sites.

Methods
Cross/inked fibrinogen and fibrin. Normal fibrinogen fraction I-2 was
prepared as previously described ( 22). Tokyo II fibrinogen was prepared

as described by Matsuda et al. (15). Plasma factor XIII ( 23) at a
concentration of 500 Loewy U /ml in 0.1 M NaCl, 20 mM Hepes, pH
7 buffer containing 50 mM OTT, was activated to XIIIa by adding
human a-thrombin (Enzyme Research Laboratories, South Bend, IN;
specific activity, 3.4 U/mg) at 5 U/ml, final concentration, and incubating the mixture at 37°C for 30 min. For preparing crosslinked fibrinogen,
the thrombin was then inactivated by adding a tenfold excess of hirudin
(Sigma Chemical Co, St Louis, MO) (50 U/ml, final concentration).
Hirudin-treated factor XIIIa had no measureable residual thrombin activity as assessed by its failure to release detectable FPA from fibrinogen
( 24) at a final factor XIIIa concentration of l 00 U /ml over a 24 hour
incubation period, or to cleave the fibrinogen Aa chain as assessed by
SOS-PAGE of reduced fibrinogen specimens.'
For SOS-PAGE analyses of fibrinogen or fibrin crosslinking, factor
XIIIa (50 to 100 U/ml, final concentration) containing hirudin-inactivated thrombin or active thrombin (not hirudin treated), respectively,
was added to a fibrinogen solution (I mg/ml final) in 0.1 M NaCl, 20
mM Hepes, pH 7 buffer containing 10 mM CaCl 2 and incubated at
room temperature for up to 24 h. At selected time intervals, the crosslinking reaction was terminated by adding an equal volume of 5% SOS, 10
mM Tris, I mM EDTA, 10% ,8-mercaptoethanol, pH 8 solution, and
the samples subjected to electrophoresis on 8-25% gradient gels in
a Phast gel apparatus (Pharmacia/LKB). Densitometric scanning of
Coomassie blue stained gels was carried out at 540 nm in a Gilford
Response UV-VIS spectrophotometer.
Fibrin for scanning electron microscopy ( SEM). Fibrin was formed
directly on carbon-formvar coated gold grids by adding I µI thrombin
( 0.5 U /ml) to a 4 µI droplet of fibrinogen at 500 µg/ml in l O mM Tris,
0.15 M NaCl, pH 7.4 buffer, and incubating the clotting mixture overnight at room temperature. CaCI,, 10 mM final concentration, was added
to some clotting mixtures. The clots were then fixed with 2.5% glutaraldehyde in 0.1 M Hepes pH 7 buffer, containing 0.2% tannic acid,
and washed several times with Hepes buffer. These specimens were
dehydrated in graded ethanol solutions ( 20% to l 00%), CO2 critical
point dried using a Tousimis model 780A critical point drying apparatus,

Tokyo II
-Ca

2+

+Ca

2+

Normal

Figure 2. SEM images of Tokyo II fibrin (A
and B) and normal fibrin (C and D). Fibrin
formed in Hepes pH 7 buffer are at the left
(A and C), and fibrin formed in the same
buffer containing 10 mM CaCI, are at the right
(Band D) . Bar, 10 µm.
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Table I. Assessment of Constitutive D Domain Polymerization or Association Sites on Tokyo II Fibrinogen
Fibrin assembly
(thrombin time)

D domain site

Binding to
fibrin sepharosc

Fibrin
crosslinking rate

Normal

Normal

Normal

Normal

D:E ('a' site)

-yXL:-yXL
Abnormal (prolonged)

D:D

Fibrinogen
crosslinking rate

Crosslinked
fibrinogen fibrils

Normal
Normal

Disordered

The experimental results that define the constitutive polymerization or intermolecular association sites on fibrinogen Tokyo II, are indicated.

A

and coated with 5 nm platinum in a VCR IBS/TM200S Ion Beam
Sputter System. SEM was carried out in a JOEL JSM6300F Field Emission Scanning Electron Microscope.

Fibrinogen
Tokyo II

Normal
Aap[

--

y-y.....__
Aa......_

-

--

: : ...........

spy'T

fgn O' 5' 10' 30' 2h 24h

fgn O'

Scanning transmission electron microscopic (STEM) analysis of
crosslinked fibrinogen polymers. To prepare electron microscope grids
of fresh, partially crosslinked fibrinogen for STEM analyses, factor
XIIIa/fibrinogen crosslinking mixtures, prepared as described above,
were deposited as 50 µl drops on a parafilm surface and incubated at
room temperature for 10-20 min. At the selected time interval, a specimen was mixed by drawing the solution back and forth several times
into a shortened plastic pipette tip, and diluted to 5-10 µg/ml in the
Hepes pH 7 buffer. 3 µI was then injected into a 3-µ1 droplet of the
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Figure 3. Factor XIIIa crosslinking of Tokyo II fibrinogen or fibrin
assessed by SDS-PAGE. A, hirudin-treated factor XIIIa (100 U/ml,
final) was added to normal or Tokyo II fibrinogen to produce fibrinogen
crosslinking mixtures (upper panels). Non-hirudin treated factor XIIIa
was added to produce fibrin crosslinking mixtures ( lower panels). Sampling times are indicated beneath the gels; (B) a plot of the densitometric
scan of the -y and 'Y'Y band positions expressed as the ratio of 'Y'Y to -y
+ 'Y'Y. ( •) Normal fibrinogen or fibrin; ( o) Tokyo II fibrinogen or
fibrin.

Figure 4. STEM images obtained from a ten minute sample of a crosslinking mixture of normal fibrinogen in pH 7 Hepes buffer, showing
examples of the double-stranded fibrils that form as a result of -y chain
crosslinking. Fibrinogen molecules become aligned within a fibril strand,
and form end-to-end DD complexes between neighboring molecules
(brackets), as a result of the D:D self-association reaction. A schematic
diagram illustrating the molecular arrangement is shown in panel B.
Some of the thin filaments ( representing crosslinked -y chains) that
connect the D domains of fibril strands are indicated by arrows. Bar,
100 nm.
Polymerization of Fibrin and Fibrinogen Tokyo II
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Figure 5. STEM images obtained from a
ten minute sample of a crosslinking mixture of Tokyo II fibrinogen in pH 7 Hepes
buffer, showing examples of the aggregates and short double-stranded fibrils that
form as a result of 'Y chain crosslinking.
Disordered crosslinked fibrinogen polymers form as a result of the presence of
defective D:D self-association sites
(A-E). Tokyo II fibrinogen molecules
sometimes form short double-stranded fibrils, probably resulting from competent
D:D self-association reactions (A, C, and
F). Factor Xllla molecules are indicated
by open arrowheads. Bar, 100 nm.

same buffer on the surface of a carbon-coated electron mic;roscope grid,
and the specimen allowed to attach to the grid surface for I min ( 25).
The fluid on the grid surface was then exchanged 8-10 times with 150
mM ammonium acetate solution, frozen in liquid nitrogen, freeze-dried,
transferred under vacuum to the microscope stage, and imaged at the
Brookhaven STEM facility using a 40 kv probe focused at 0.25 nm.
Background filtering of digitized STEM images was optimized for contrast and brightness offset by an image processing program (Adobe
Photoshop), and the adjusted images downloaded to a GCC Technologies ColorFast film recorder.

Results
Tokyo 11 fibrin. The Tokyo II fibrin clot formed an extensively
branched fiber network that had a lower fiber density than normal fibrin, and was featured by the presence of numerous tapered terminating fibers ( Fig. 2 A) . Including calcium ions in
the Tokyo II clotting mixture resulted in somewhat greater fiber
density and thinner fibers, but the extensive branching and tapering terminal fibers remained (Fig. 2 B). Morphological differences in normal fibrin matrix structure in the presence or ab1056
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sence of calcium ions were minimal. The greater widths of
Tokyo II fibers in buffer compared with normal fibrin or Tokyo
II fibrin formed in the presence of calcium, is probably related
to the slow kinetics of Tokyo II fibrin assembly in buffer, since
slowly polymerizing clots develop thicker fiber bundles than
more rapidly formed clots ( 8, 26-28) .
The cross linking rates of Tokyo II fibrinogen and fibrin. A
summary of the various evaluations of Tokyo II fibrinogen/
fibrin function, that result in determination of the competency
of its polymerization or self-association sites is given in Table
I. The crosslinking rate of Tokyo II fibrinogen y and Aa chains
was the same as for normal fibrinogen, as assessed by visual
inspection (Fig. 3 A) and by densitometric gel scanning (Fig.
3 B). Complete y chain crosslinking was observed for both
normal and Tokyo II fibrin at the earliest time point (5 min),
suggesting that their crosslinking rates were the same. When
the fibrin crosslinking experiment was repeated under the same
conditions with earlier sampling, complete y chain crosslinking
occurred at the earliest sampling time ( 1 min; data not shown),
indicating that fibrin y chain crosslinking is at least 40-fold
faster than that of each respective fibrinogen. These observa-

Flbrinogen

Figure 6. Schematic diagram showing the molecular arrangement of
factor XIIIa-crosslinked normal and Tokyo D fibrinogen. The end-toend association between normal D domains of fibrinogen at the functional D:D self-association site is indicated, as is the location of the
'YXL:'YXL self-association site within which the 'Y chain crosslinlcing site
is situated. Gamma chain crosslinking between strands results in parallel
fibrils with ~22.5 nm periodicity.• In the bottom part of the diagram,
disordered assembly of crosslinked fibrinogen molecules derived from
the heterozygotic Tokyo D subject, is depicted. The D domains of Tokyo
D fibrinogen molecules containing a defective D:D polymerization site
are unfilled; normal D:D sites are hatched.

tions are consistent with our recent findings on the differences
between the crosslinking rates of normal fibrinogen and fibrin, 1
and confirms the conclusion that the fibrin D:E association accounts for the higher crosslinking rate of fibrin over fibrinogen
(29, 30). The fact that Tokyo II fibrinogen manifests the same
degree of accelerated crosslinking as normal fibrin, provides
confirmation for the previous finding based on fibrin affinity
chromatography experiments that the D:E interaction in Tokyo
II is normal (15).
Cross/inked Tokyo II fibrinogen polymer structure. Normal
fibrinogen that had been crosslinked in the presence of factor
XIIIa formed elongated double-stranded fibrils (Fig. 4 ),
whereas Tokyo II fibrinogen did not (Fig. 5). The constituent
fibrinogen molecules within each normal fibrinogen fibril strand
were aligned end-to-end to form the intermolecular DD complexes that resulted from the 'D:D' association reaction, and
the fibril strands became aligned in parallel because of the 'Y
chain crosslinks that bridge the fibril strands. The half-staggered
arrangement of molecules constituting the fibrinogen fibrils
causes them to have 22.5 nm periodicity. 1
Crosslinked Tokyo II fibrinogen, although it had become
crosslinked at the same rate and to the same extent as normal
fibrinogen ( Fig. 3), formed polymeric structures that were not
as well ordered as normal crosslinked fibrinogen fibrils (Fig.
5). Most commonly, Tokyo II fibrinogen formed aggregated
collections of crosslinked molecules, with occasional short double-stranded fibrillar segments with ~ 22.5 nm periodicity
(Fig. 5 A, C, and F). These 'normal' fibril segments probably
reflect a subpopulation of Tokyo II fibrinogen molecules having
two functionally normal D domains (i.e., "normal homodimers'' ) , that are present in the heterozygous fibrinogen population (Fig. 6).

Discussion
Our recent studies on fibrinogen crosslinking I led to recognition
of the existence and general location of two constitutive intermolecular association sites on fibrinogen D domains, that are
distinct from the D domain 'a' polymerization site that interacts
with an exposed 'A' site in the fibrin E domain (D:E). These
sites evidently participate in fibrin assembly, and have the following defining characteristics: 'YXL:'YXL -this site is in the carboxy terminal region of the 'Y chain and overlaps the 'Y chain
crosslinking site. The site is recognizable from ultrastructural
analyses of crosslinked or uncrosslinked fibrinogen, and from
kinetic studies of fibrinogen and fibrin crosslinking; 1 and D:Dthis site is located at the outer end of each fibrinogen D domain
and was identified from ultrastructural analyses of native fi.
brinogen solutions showing frequent noncovalent D-to-D associations 1 (Table I). The existence of a D:D self-association site
has also been suggested from other studies on fibrinogen or
fibrin assembly (19-21) .
Previous studies had indicated that the fibrin D:E interaction
was normal in Tokyo II fibrin, and that factor XIIIa-mediated
crosslinking of Tokyo II fibrin was also normal ( 15). Our present studies extend those observations to show that the rate as
well as the extent of crosslinking of fibrin Tokyo II is the same
as that of its normal counterpart, strongly reinforcing the notion
of a normal D:E interaction. The fact that the crosslinking rate
of Tokyo II fibrinogen is also the same as its normal counterpart
indicates that 'YXL :'YXL self-association sites are normal. Despite
this, assembly of crosslinked Tokyo II fibrinogen is grossly
abnormal, thus pointing directly to a defective D:D self-association site interaction. This heterozygous deficiency, which is
caused by y275 arg"""Cys mutations involving half the fibrinogen
D domains, results in abnormal end-to-end associations during
factor XIIIa-catalyzed fibrinogen polymer assembly and also, as
assessed by morphological appearances, during fibrin assembly.
Thus, these studies on Tokyo II fibrin and crosslinked fibrinogen
polymer structure, advance our understanding of the specific
self-association sites that participate in the fibrin assembly process. They indicate that the D:E interaction is necessary but not
alone sufficient for fibril assembly, and that the D:D interaction
is also required.
Our findings also indicate that the D:D interaction is an
important determinant of the ultimate network structure of the
fibrin clot. The Tokyo II fibrin network is more highly branched
than its normal counterpart (Fig. 2), an observation that is very
similar to those we have made on fibrinogens having a mutation
at the same site-Haifa ( y275 arg-+his) ( 31 ) and Morioka
( y275 arg"""Cys) ( 32) . The likely explanation for increased
branching is that impairment of intermolecular D:D interactions
permits fibrin molecules to extend outward from linearly propagating fibril strands more frequently, thus favoring formation
of greater numbers of branch points ( 25).
The abnormality in Tokyo II D dimer binding to the fibrin
E domain had tentatively been attributed to a defect in a region
expressed in the linearly aligned dimeric D domain ( 'bb') that
participates in lateral fibril association ( 18) via interaction with
an exposed 'B' site in the fibrin E domain. Based upon our
present observations on crosslinked fibrinogen polymers, in
which the fibrinogen E domain plays no obvious role in the
assembly process, this surmise does not seem to be the case.
Our findings indicate instead that the primary defect in the
Tokyo II molecule, as formerly reflected in its defective D
Polymerization of Fibrin and Fibrinogen Tokyo II
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dimer function, is due to an abnormality in self-association of its
constituent D domains that results in defective fibril assembly.
Lateral association of thrombin-cleaved fibrin fibrils due to the
'bb' site interaction may prove to be related to the D:D interaction, requiring DD association for full expression, or it may be
related less directly to DD assembly. These possibilities remain
to be investigated.
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